Annual Drug Patent Expirations for OPZELURA
Opzelura is a drug marketed by Incyte Corp and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug.
Drug patent litigation for OPZELURA.
This drug has two hundred and forty patent family members in forty-seven countries.
The generic ingredient in OPZELURA is ruxolitinib phosphate. One supplier is listed for this compound. Additional details are available on the ruxolitinib phosphate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
